Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Yale Univ

Neither a doctor nor a teaching hospital

Research payments

$2,263,193

676 payments

Through program year 2025, Yale Univ is reported as receiving $2,263,193 in research payments, across 676 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $577,284 157
2024 Research $427,093 63
2023 Research $382,087 48
2022 Research $473,673 51
2021 Research $208,055 302
2020 Research $148,944 36
2019 Research $46,057 19

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $937,115 219 payments
  2. Siemens Medical Solutions USA, Inc. $625,112 17 payments
  3. Novo Nordisk Inc $326,394 8 payments
  4. Novo Nordisk AS $169,924 375 payments
  5. Ipsen Pharma SAS $102,534 31 payments
  6. Ipsen Innovation $35,860 11 payments
  7. Janssen Global Services, LLC $31,615 6 payments
  8. Janssen Scientific Affairs, LLC $16,200 2 payments
  9. Ipsen Bioscience Inc $10,790 3 payments
  10. Cordis Corporation $5,850 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years $455,367 43 payments
  2. Japan Post Market Study OCT/IVUS $247,083 1 payment
  3. Evaluating the Prevalence and Healthcare Utilization Patterns of Atherosclerotic Cardiovascular Disease and Heart Failure in Patients with Type-2 Diabetes $191,657 4 payments
  4. Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis $104,779 20 payments
  5. An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours $102,534 31 payments
  6. Ex9536-4388 $101,787 191 payments
  7. A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS) $85,509 45 payments
  8. Development and Validation of Dynamic PET Imaging Aproach for Quantitative Assessment of Flow in Patients with DM and PAD $75,000 1 payment
  9. Development and Validation of Dynamic PET Imaging Approach for Quantitative Assessment in Flow in Patients with DM and PAD $75,000 1 payment
  10. Iss-001493 $70,995 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record